Skip to main content
Figure 6 | Arthritis Research & Therapy

Figure 6

From: Suppression of endothelial cell activity by inhibition of TNFα

Figure 6

Certolizumab pegol inhibits TNFα-induced endothelial cell tube formation in Matrigel. Photomicrographs (×40) of representative wells are shown. The increase in tube formation in the TNFα-induced human dermal microvascular endothelial cell (HMVEC) group and the decreased angiogenesis in certolizumab pegol groups are shown as well as the control groups: (A) PBS, (B) basic fibroblast growth factor (bFGF; 60 nM), (C) TNFα (0.1 ng/ml), (D) TNFα (0.1 ng/ml) in the presence of certolizumab pegol (0.1 μg/ml), and (E) TNFα (0.1 ng/ml) with mouse-IgG (Ms-Ig; 0.1 μg/ml). Arrows represent the endothelial cell (EC) tube formation in Matrigel. (F) HMVECs form significantly greater number of tubes in Matrigel in response to TNFα at 0.1 ng/ml (94% increase) versus the PBS control group (*P < 0.05). (G) HMVECs were plated in Matrigel and incubated with either PBS (negative control), bFGF (60 nM; positive control) or TNFα (0.1 ng/ml) with graded concentrations of certolizumab pegol (0.1 μg/ml, n = 7; 1.0 μg/ml, n = 8; or 10.0 μg/ml, n = 4) or, for comparison, Ms-Ig (0.1 μg/ml, n = 8; 1.0 μg/ml, n = 4; or 10.0 μg/ml, n = 4). As shown, certolizumab pegol (0.1 or 1.0 μg/ml) blocks TNFα-induced EC tube formation in Matrigel compared with the Ms-Ig control groups (33% and 30% decreases in tube formation, respectively; *P < 0.05; n, number of independent experiments performed). For all sets of experiments, means of the number of tubes per well are given ± standard error of the mean.

Back to article page